Sialix Cancer Research
Recent Finacing
Equity
Recent Raise
$1.2M
Sialix develops therapeutic antibodies and a prophylactic nutritional supplement via a proprietary platform targeting non-human sialic acid–mediated glycan alterations implicated in cancer and inflammation.
Highlights
Focus Areas
Biotechnology
Health Care
Oncology
Recent Investors
Financials
$2.2M
Total Raised
2
Funding rounds
6
Investors